These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38194601)

  • 1. Managing Impending Nonsevere Hypoglycemia With Oral Carbohydrates in Type 1 Diabetes: The REVERSIBLE Trial.
    Cheng R; Taleb N; Wu Z; Bouchard D; Parent V; Lalanne-Mistrih ML; Boudreau V; Messier V; Lacombe MJ; Grou C; Brazeau AS; Rabasa-Lhoret R
    Diabetes Care; 2024 Mar; 47(3):476-482. PubMed ID: 38194601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-severe hypoglycemia in type 1 diabetes: a randomized crossover trial comparing two quantities of oral carbohydrates at different insulin-induced hypoglycemia ranges.
    Taleb N; Gingras V; Cheng R; Parent V; Messier V; Bovan D; Shohoudi A; Brazeau AS; Rabasa-Lhoret R
    Front Endocrinol (Lausanne); 2023; 14():1186680. PubMed ID: 37334295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes Using Oral Carbohydrates During Automated Insulin Delivery With and Without Glucagon.
    Taleb N; Cheng R; Wu Z; Messier V; Desjardins K; Rabasa-Lhoret R
    Can J Diabetes; 2023 Jul; 47(5):445-450. PubMed ID: 37088417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.
    Laugesen C; Ranjan AG; Schmidt S; Nørgaard K
    Diabetes Care; 2022 Jun; 45(6):1391-1399. PubMed ID: 35475907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
    Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower versus standard sucrose dose for treating hypoglycemia in patients with type 1 diabetes mellitus in therapy with predictive low glucose suspend (PLGS) augmented insulin pumps: A randomized crossover trial in Santiago, Chile.
    Grassi B; Onetto MT; Zapata Y; Jofré P; Echeverría G
    Diabetes Metab Syndr; 2021; 15(3):695-701. PubMed ID: 33813244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between pre-ramadan glycemic control and subsequent glucose fluctuation during fasting in adolescents with Type 1 diabetes.
    Afandi B; Kaplan W; Al Hassani N; Hadi S; Mohamed A
    J Endocrinol Invest; 2017 Jul; 40(7):741-744. PubMed ID: 28239763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mild-to-moderate hypoglycemia in patients with type 1 diabetes treated with insulin pump therapy: are current recommendations effective?
    Gingras V; Desjardins K; Smaoui MR; Savard V; Messier V; Haidar A; Legault L; Rabasa-Lhoret R
    Acta Diabetol; 2018 Mar; 55(3):227-231. PubMed ID: 29224132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of Inpatient CGM: Comparison to Standard of Care.
    Price C; Ditton G; Russell GB; Aloi J
    J Diabetes Sci Technol; 2023 Mar; 17(2):329-335. PubMed ID: 34911384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.
    Torres Roldan VD; Urtecho M; Nayfeh T; Firwana M; Muthusamy K; Hasan B; Abd-Rabu R; Maraboto A; Qoubaitary A; Prokop L; Lieb DC; McCall AL; Wang Z; Murad MH
    J Clin Endocrinol Metab; 2023 Feb; 108(3):592-603. PubMed ID: 36477885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Basal Insulin Suspension at the Start of Exercise on Blood Glucose Levels During Continuous Versus Circuit-Based Exercise in Individuals with Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion.
    Zaharieva D; Yavelberg L; Jamnik V; Cinar A; Turksoy K; Riddell MC
    Diabetes Technol Ther; 2017 Jun; 19(6):370-378. PubMed ID: 28613947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical decision support to improve management of diabetes and dysglycemia in the hospital: a path to optimizing practice and outcomes.
    Pichardo-Lowden A; Umpierrez G; Lehman EB; Bolton MD; DeFlitch CJ; Chinchilli VM; Haidet PM
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33462075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control.
    Famulla S; Hövelmann U; Fischer A; Coester HV; Hermanski L; Kaltheuner M; Kaltheuner L; Heinemann L; Heise T; Hirsch L
    Diabetes Care; 2016 Sep; 39(9):1486-92. PubMed ID: 27411698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
    Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
    Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overnight closed-loop insulin delivery with model predictive control: assessment of hypoglycemia and hyperglycemia risk using simulation studies.
    Wilinska ME; Budiman ES; Taub MB; Elleri D; Allen JM; Acerini CL; Dunger DB; Hovorka R
    J Diabetes Sci Technol; 2009 Sep; 3(5):1109-20. PubMed ID: 20144424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.
    Holcombe JH; Zalani S; Arora VK; Mast CJ;
    Clin Ther; 2002 Apr; 24(4):629-38. PubMed ID: 12017407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Continuous Glucose Monitoring Trends to Facilitate Exercise in Children with Type 1 Diabetes.
    Burckhardt MA; Chetty T; Smith GJ; Adolfsson P; de Bock M; Jones TW; Davis EA
    Diabetes Technol Ther; 2019 Jan; 21(1):51-55. PubMed ID: 30620642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.